Table: q1_q4_2021_prescription_drugs_intro_to_market , manufacturer_name like Q*

A  B  C  D  E  F  G  H  I  J  K  L  M  N  O  P  Q  R  S  T  U  V  W  X  Y  Z  *

manufacturer_name	ndc_number	drug_product_description	date_introduced_to_market	wac_at_introduction	marketing_pricing_plan_description	marketing_pricing_plan_non_public_indicator	estimated_number_of_patients	breakthrough_therapy_indicator	priority_review_indicator	acquisition_date	acquisition_price	acquisition_price_non_public_indicator	acquisition_price_comment	general_comments	supporting_documents
QED Therapeutics, Inc.	72730011101	Truseltiq 100mg capsules 1 blister pack	2021-06-16	21500.0000	Truseltiq (infigratinib) is a new option for 2L+ FGFR2 fusion CCA who are in need of therapeutic options after frontline therapy. QED’s approach will focus on educating physicians about CCA, NGS testing, Truseltiq and important information about treatment with targeted therapies like FGFR inhibitors. Educational materials will be provided across the patient journey, to HCPs and to consumers, and provide information about access support for Truseltiq.	None	250	None	None	None	None	None	None	Maximum potential of 250 patients (Total annual patient population in intrahepatic cholangiocarcinoma of 3,000 per year/ 12 months) Source: https://rarediseases.org/rare-diseases/cholangiocarcinoma/#:~:text=Affected%20Populations&text=The%20incidence%20of%20intrahepatic%20cholangiocarcinoma,States%20is%20increasing%20%5B7%5D	None
QED Therapeutics, Inc.	72730010101	Truseltiq 125mg capsules 1 blister pack	2021-06-16	21500.0000	Truseltiq (infigratinib) is a new option for 2L+ FGFR2 fusion CCA who are in need of therapeutic options after frontline therapy. QED’s approach will focus on educating physicians about CCA, NGS testing, Truseltiq and important information about treatment with targeted therapies like FGFR inhibitors. Educational materials will be provided across the patient journey, to HCPs and to consumers, and provide information about access support for Truseltiq.	None	250	None	None	None	None	None	None	Maximum potential of 250 patients (Total annual patient population in intrahepatic cholangiocarcinoma of 3,000 per year/ 12 months) Source: https://rarediseases.org/rare-diseases/cholangiocarcinoma/#:~:text=Affected%20Populations&text=The%20incidence%20of%20intrahepatic%20cholangiocarcinoma,States%20is%20increasing%20%5B7%5D	None
QED Therapeutics, Inc.	72730050601	Truseltiq 50mg capsules 1 blister pack	2021-06-16	21500.0000	Truseltiq (infigratinib) is a new option for 2L+ FGFR2 fusion CCA who are in need of therapeutic options after frontline therapy. QED’s approach will focus on educating physicians about CCA, NGS testing, Truseltiq and important information about treatment with targeted therapies like FGFR inhibitors. Educational materials will be provided across the patient journey, to HCPs and to consumers, and provide information about access support for Truseltiq.	None	250	None	None	None	None	None	None	Maximum potential of 250 patients (Total annual patient population in intrahepatic cholangiocarcinoma of 3,000 per year/ 12 months) Source: https://rarediseases.org/rare-diseases/cholangiocarcinoma/#:~:text=Affected%20Populations&text=The%20incidence%20of%20intrahepatic%20cholangiocarcinoma,States%20is%20increasing%20%5B7%5D	None
QED Therapeutics, Inc.	72730020201	Truseltiq 75mg capsules 1 carton pack (2 blister packs)	2021-06-16	21500.0000	Truseltiq (infigratinib) is a new option for 2L+ FGFR2 fusion CCA who are in need of therapeutic options after frontline therapy. QED’s approach will focus on educating physicians about CCA, NGS testing, Truseltiq and important information about treatment with targeted therapies like FGFR inhibitors. Educational materials will be provided across the patient journey, to HCPs and to consumers, and provide information about access support for Truseltiq.	None	250	None	None	None	None	None	None	Maximum potential of 250 patients (Total annual patient population in intrahepatic cholangiocarcinoma of 3,000 per year/ 12 months) Source: https://rarediseases.org/rare-diseases/cholangiocarcinoma/#:~:text=Affected%20Populations&text=The%20incidence%20of%20intrahepatic%20cholangiocarcinoma,States%20is%20increasing%20%5B7%5D	None